Joël Guigay
Impact in
- Otorhinolaryngology top 0.05%
- Head and Neck Cancer Studies
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- CAR-T cell therapy research
Papers in
-
- Head and Neck Cancer Studies 78
- Oncology 56
- Cancer Immunotherapy and Biomarkers 16
- Lung Cancer Research Studies 15
- Cancer Diagnosis and Treatment 15
- Co-authors
- Esma Saâda-Bouzid (18 shared papers)Jérôme Fayette (21 shared papers)Frédéric Peyrade (20 shared papers)Caroline Even (19 shared papers)Christophe Le Tourneau (12 shared papers)Pierre Busson (4 shared papers)Dana M. Hartl (6 shared papers)Jean Bourhis (15 shared papers)
- Journals
- Annals of Oncology (29 papers)European Journal of Cancer (14 papers)Oral Oncology (8 papers)Current Opinion in Oncology (8 papers)European Annals of Otorhinolaryngology Head and Neck Diseases (4 papers)
- Partner nations
- FranceUnited StatesItaly
In The Last Decade
Joël Guigay
162 papers receiving 10.5k citations
Joël Guigay's Hit Papers
Peers
Comparison fields: 5 of 125
- Otorhinolaryngology 3.0k
- Oncology 5.3k
- Immunology 1.7k
- Cancer Research 945
- Pulmonary and Respiratory Medicine 1.7k
Countries citing papers authored by Joël Guigay
This map shows the geographic impact of Joël Guigay's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joël Guigay with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joël Guigay more than expected).
Fields of papers citing papers by Joël Guigay
This network shows the impact of papers produced by Joël Guigay. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joël Guigay. The network helps show where Joël Guigay may publish in the future.
Co-authors
The 25 scholars most cited alongside Joël Guigay, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 167 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck Hit paper breakdown → | 2016 | 4042 |
| 2 | Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression Hit paper breakdown → | 2018 | 633 |
| 3 | Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma Hit paper breakdown → | 2017 | 492 |
| 4 | 2008 | 373 | |
| 5 | Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial Hit paper breakdown → | 2017 | 347 |
| 6 | Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial Hit paper breakdown → | 2015 | 333 |
| 7 | 2013 | 275 | |
| 8 | 2014 | 195 | |
| 9 | 2014 | 188 | |
| 10 | Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial Hit paper breakdown → | 2021 | 157 |
| 11 | 2009 | 149 | |
| 12 | 2017 | 144 | |
| 13 | 2019 | 140 | |
| 14 | Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial Hit paper breakdown → | 2022 | 133 |
| 15 | 2019 | 131 | |
| 16 | 2015 | 125 | |
| 17 | 2010 | 117 | |
| 18 | 2015 | 114 | |
| 19 | 2009 | 104 | |
| 20 | 2017 | 93 |
About Joël Guigay
Joël Guigay is a scholar working on Otorhinolaryngology, Oncology, Pulmonary and Respiratory Medicine, Epidemiology and Surgery, having authored 167 papers that have together received 10.7k indexed citations. Recurring topics across this work include Head and Neck Cancer Studies (78 papers), Lung Cancer Treatments and Mutations (26 papers), Neuroendocrine Tumor Research Advances (18 papers), Cancer Immunotherapy and Biomarkers (16 papers), Lung Cancer Research Studies (15 papers), Cancer Diagnosis and Treatment (15 papers), Colorectal and Anal Carcinomas (9 papers) and Salivary Gland Tumors Diagnosis and Treatment (8 papers). The work is most often cited by research in Otorhinolaryngology (3.0k citations), Oncology (5.3k citations), Immunology (1.7k citations), Cancer Research (945 citations) and Pulmonary and Respiratory Medicine (1.7k citations). Joël Guigay has collaborated with scholars based in France, United States and Italy. Frequent co-authors include Esma Saâda-Bouzid, Jérôme Fayette, Frédéric Peyrade, Caroline Even, Christophe Le Tourneau, Pierre Busson, Dana M. Hartl, Jean Bourhis, Éric Baudin and Michel Pierre Ducreux. Their work appears in journals such as Annals of Oncology, European Journal of Cancer, Oral Oncology, Current Opinion in Oncology and European Annals of Otorhinolaryngology Head and Neck Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.